Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently.
Dr. Sandy Srinivas
Principal Investigator
Stanford University
United States: Institutional Review Board
PROS0001
NCT00226954
March 2003
February 2009
Name | Location |
---|---|
Stanford University School of Medicine | Stanford, California 94305-5317 |